RxDoctor Payments Data

Abdul Shadani, MD

Cardiovascular Disease · Ft. Pierce, FLNPI 1467593681

Payments from drug & device makers

$962in general payments, 2019–2025

Across 16 payments — averaging $60.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$676
  • Abiomed$125
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$56
  • Pfizer$55
  • Kestra Medical Technology Services, Inc.$28
  • Cordis US CORP.$22

What the payments were for

  • Travel & lodging$40642%
  • Food & beverage$55658%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$962 in reported general payments places this provider in the 25th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$231,118
Medicare patients
680
Services billed
2,552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban325$324,091
XareltoRivaroxaban85$86,829
EntrestoSacubitril/Valsartan51$57,584
BrilintaTicagrelor16$9,534
JardianceEmpagliflozin11$8,857
Doxazosin Mesylate291$5,854
Potassium Chloride258$4,284
Metoprolol Tartrate422$2,748
Isosorbide Mononitrate ErIsosorbide Mononitrate174$2,672
Diltiazem 12hr ErDiltiazem Hcl13$2,614
Atorvastatin Calcium276$2,536
Losartan Potassium271$2,126
ClopidogrelClopidogrel Bisulfate238$1,709
Diltiazem 24hr Er (Cd)Diltiazem Hcl58$1,494
Nifedipine ErNifedipine31$1,390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$55$324,091325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Ft. Pierce

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →